Artifact GuideEU

EU Medical Device Regulation Transition Timelines

The EU MDR governs medical devices placed on the EU market, including qualification, classification, conformity assessment, technical documentation, clinical evidence, PMS, vigilance, UDI, and EUDAMED obligations.

Use this page to turn Transition Timelines into clear scope decisions, owner actions, evidence records, and source-linked next steps.

Back to main artifactReview sources
Author
Sorena AI
Published
May 9, 2026
Updated
May 9, 2026
Sections
3

Structured answer sets in this page tree.

Primary sources
5

Cited legal and guidance references.

Publication metadata
Sorena AI
Published May 9, 2026
Updated May 9, 2026
Overview

Transition Timelines under EU Medical Device Regulation is a practical compliance question: decide scope, map the duty to the cited source, assign an owner, and keep evidence that can survive release reviews, procurement questions, and authority requests.

Section 1

Which EU Medical Device Regulation dates matter for Transition Timelines?

Use the timeline as a decision tool, not only as a date list. The important question is what a date changes: scope, transition status, evidence readiness, authority powers, conformity route, contract handling, or corrective-action timing.

For EU MDR, the practical timing baseline is MDR application from 26 May 2021, transition conditions amended in 2023, QMS and notified-body application milestones in 2024, and risk-class transition end dates through 2027 and 2028 where conditions are met. Check the underlying source before relying on a date in a launch, recall, certificate, procurement, or authority-response workflow.

  • 26 May 2021: Regulation (EU) 2017/745 became the main application date after the one-year postponement in Regulation (EU) 2020/561.
  • 15 March 2023: Regulation (EU) 2023/607 amended the MDR transitional provisions.
  • 26 May 2024: manufacturers relying on the extended transition must have a quality management system in place and a formal application lodged with a notified body by this date; the written agreement must follow by 26 September 2024.
  • 26 May 2026: class III custom-made implantable devices may be placed on the market or put into service until this date if the stated conditions are met.
  • 31 December 2027: class III devices and class IIb implantable devices listed in Article 120(3a)(a) may be placed on the market or put into service until this date.
  • 31 December 2028: class IIb devices not listed in Article 120(3a)(a), class IIa devices, and class I devices placed on the market in sterile condition or having a measuring function may be placed on the market or put into service until this date.
  • Devices without a notified body requirement under Directive 93/42/EEC, but that need one under the MDR, may be placed on the market or put into service until 31 December 2028 if the Article 120(3c) conditions are met.
Sources for this answer
Regulation (EU) 2017/745 on medical devices
Binding MDR source for scope, device classification, conformity assessment, technical documentation, clinical evidence, PMS, vigilance, and UDI.
Regulation (EU) 2023/607 on MDR and IVDR transitional provisions
Binding amendment source for MDR transition conditions and legacy-device timing.
MDCG 2022-7 - UDI system Q&A
MDCG guidance source for UDI-DI, Basic UDI-DI, and UDI data questions.
European Commission - EUDAMED UDI/device registration
Commission EUDAMED source for device registration context.
Section 2

What evidence should be kept for Transition Timelines under EU Medical Device Regulation?

Keep evidence that a reviewer can follow without knowing the project history. The file should show what was assessed, what rule was applied, what was tested or reviewed, what changed, who approved it, and what still needs monitoring.

For EU MDR, the core evidence set is qualification rationale, classification rule memo, notified-body route, QMS records, technical documentation, clinical evaluation, PMCF/PMS plans, vigilance records, UDI data, and EUDAMED submissions. Add a short assumptions note to explain assumptions, exclusions, and unresolved issues.

  • Maintain a dated scope memo and cross-reference it to Regulation (EU) 2017/745.
  • Attach standards, tests, declarations, supplier inputs, authority correspondence, and remediation logs where they support the conclusion.
  • Reopen the record when the product, supplier, market, harmonised standard, guidance, or legal deadline changes.
Sources for this answer
Regulation (EU) 2017/745 on medical devices
Binding MDR source for scope, device classification, conformity assessment, technical documentation, clinical evidence, PMS, vigilance, and UDI.
Regulation (EU) 2023/607 on MDR and IVDR transitional provisions
Binding amendment source for MDR transition conditions and legacy-device timing.
MDCG 2022-7 - UDI system Q&A
MDCG guidance source for UDI-DI, Basic UDI-DI, and UDI data questions.
European Commission - EUDAMED UDI/device registration
Commission EUDAMED source for device registration context.
Recommended next step

Use this EU MDR guide as a cited evidence workflow

Turn this EU Medical Device Regulation page into a repeatable workflow for product, legal, quality, procurement, support, and engineering teams. Keep citations, owners, evidence, and review triggers together.

Research workflow
Open Research Copilot

Answer EU MDR scope, timing, and interpretation questions with cited outputs.

Explore next step
Talk to Sorena
Talk through implementation

Review your scope, evidence model, controls, and next actions.

Explore next step
Section 3

Implementation checklist for Transition Timelines under EU Medical Device Regulation

Treat the checklist as a decision workflow, not as a static policy. The goal is to get a documented yes/no/needs-escalation answer that product, legal, quality, regulatory, and support teams can reuse.

  • Confirm the exact product, service, role, and market placement fact pattern.
  • Map the relevant obligation to a source, owner, artifact, and due date.
  • Decide whether harmonised standards, notified-body input, supplier declarations, test evidence, or authority guidance are needed.
  • Write the residual-risk, exception, or escalation decision in plain language.
  • Schedule review after release, supplier change, incident, complaint, standard update, or regulatory amendment.
Sources for this answer
Regulation (EU) 2017/745 on medical devices
Binding MDR source for scope, device classification, conformity assessment, technical documentation, clinical evidence, PMS, vigilance, and UDI.
Regulation (EU) 2023/607 on MDR and IVDR transitional provisions
Binding amendment source for MDR transition conditions and legacy-device timing.
MDCG 2022-7 - UDI system Q&A
MDCG guidance source for UDI-DI, Basic UDI-DI, and UDI data questions.
European Commission - EUDAMED UDI/device registration
Commission EUDAMED source for device registration context.
Primary sources

References and citations

European Commission - harmonised standards overview
single-market-economy.ec.europa.eu
Referenced sections
  • Official Commission overview used for standards, OJEU citation, and presumption-of-conformity context.
"Harmonised standards are European standards adopted on the basis of a request."
MDCG 2022-7 - UDI system Q&A
health.ec.europa.eu
Referenced sections
  • MDCG guidance source for UDI-DI, Basic UDI-DI, and UDI data questions.
"Unique Device Identification system"
Regulation (EU) 2017/745 on medical devices
eur-lex.europa.eu
Referenced sections
  • Binding MDR source for scope, device classification, conformity assessment, technical documentation, clinical evidence, PMS, vigilance, and UDI.
"laying down rules concerning the placing on the market"
Related guides

Explore more topics

Custom-made medical devices under the EU MDR | EU MDR FAQ
Concise EU MDR FAQ on custom-made device definition, mass-produced exclusions, Annex XIII statements, documentation, conformity assessment, PMS, vigilance, and records to retain.
EU MDR Annex II and III Technical Documentation
Build an MDR technical documentation index for Annex II device files and Annex III post-market surveillance evidence, including GSPR, risk, clinical, PMS, UDI, and EUDAMED records.
EU MDR Annex VIII Classification Guide
Classify EU MDR medical devices under Annex VIII using intended purpose, duration, invasiveness, active device and software rules, and conformity assessment impact.
EU MDR Annex XVI products without a medical purpose
source-linked EU MDR guide for Annex XVI products: listed product groups, common specifications, clinical evidence, notified-body route, UDI, EUDAMED, PMS, and vigilance evidence before launch.
EU MDR Applicability Test
Test whether a product, accessory, software function, or Annex XVI product falls under the EU Medical Device Regulation, and record the evidence for the next classification step.
EU MDR change assessment workflow
Assess EU MDR device, design, software, intended purpose, QMS, clinical, PMS, UDI, classification, and notified-body impacts before releasing a medical device change.
EU MDR Checklist for Medical Device Compliance
Practical EU MDR checklist covering qualification, classification, conformity assessment, technical documentation, GSPR, clinical evidence, UDI, EUDAMED, PMS, vigilance, QMS, and legacy transition evidence.
EU MDR classification workflow
A concrete EU MDR classification workflow for intended purpose, device or accessory qualification, Annex VIII rule selection, Rule 11 software review, class outcome, and notified body impact.
EU MDR Clinical Evaluation Overview
EU MDR clinical evaluation overview covering Article 61, Annex XIV, clinical data sources, equivalence, PMCF, CER evidence, notified body review, GSPR, and benefit-risk support.
EU MDR Clinical Evaluation Report Template
A source-linked EU MDR clinical evaluation report template covering intended purpose, GSPR linkage, clinical data appraisal, equivalence limits, PMCF, conclusions, and reviewer signoff.
EU MDR clinical evidence guide
source-linked EU MDR guide to clinical evaluation, clinical investigations, equivalence, PMCF, GSPR support, technical documentation, and notified-body review.
EU MDR compliance obligations
EU MDR compliance guide for device qualification, classification, conformity assessment, QMS, technical documentation, UDI, EUDAMED, PMS, vigilance, and legacy transition controls.
EU MDR conformity route workflow
source-linked EU MDR workflow for classifying a device, choosing the conformity assessment route, preparing technical and QMS evidence, and reaching certificate, DoC, UDI, EUDAMED, and CE outputs.
EU MDR deadlines and compliance calendar
Grounded EU MDR calendar for application, legacy-device transition, UDI, EUDAMED, and recurring QMS, technical documentation, clinical, PMS, vigilance, certificate, and change reviews.
EU MDR Device Classification Guide
Classify an EU MDR medical device by intended purpose, Annex VIII duration, invasiveness, active-device and software rules, then document the conformity route impact.
EU MDR EUDAMED and UDI registration
source-linked MDR guide to Basic UDI-DI, UDI-DI, EUDAMED device registration, actor roles, labels, technical documentation, and UDI data governance.
EU MDR FAQ: qualification, evidence, UDI, and transition
Concise EU MDR FAQ covering device qualification, software classification, accessories, custom-made devices, clinical evidence, UDI, EUDAMED, notified bodies, significant changes, and legacy transition.
EU MDR Legacy Device Transition
source-linked EU MDR legacy device transition guide covering Regulation (EU) 2023/607 conditions, certificate validity, significant-change limits, surveillance, PMS, vigilance, QMS, and evidence records.
EU MDR notified body route selection
Choose an EU MDR conformity assessment route by device class, Article 52 option, notified body designation scope, QMS readiness, technical documentation, clinical evidence, and certificate evidence.
EU MDR penalties and enforcement risk
source-linked EU MDR penalties and enforcement-risk guide covering Article 113, Member State penalty rules, market restrictions, recalls, certificate consequences, and evidence.
EU MDR PMS and Vigilance Guide
EU MDR guide to post-market surveillance, PMCF updates, PMS reports, PSURs, serious incident reporting, FSCA/FSN handling, trend reporting, and evidence records.
EU MDR PMS and vigilance records
source-linked EU MDR guide to PMS plans, PMS reports, PSURs, PMCF updates, serious incident and FSCA reporting, trend reporting, and EUDAMED evidence handling.
EU MDR PMS Plan Template for Medical Devices
A source-linked EU MDR post-market surveillance plan template covering device scope, PMS data sources, PMCF linkage, vigilance, trend reporting, PMSR or PSUR outputs, roles, cadence, and evidence records.
EU MDR QMS and technical file evidence map
Map EU MDR Article 10 QMS duties to Annex II and Annex III technical documentation, PMS, vigilance, UDI records, and notified-body review evidence.
EU MDR QMS requirements under Article 10
EU MDR QMS guide for Article 10 manufacturer controls covering regulatory strategy, design, risk, clinical evaluation, PMS, vigilance, UDI, suppliers, CAPA, and conformity records.
EU MDR qualification and borderline products
EU MDR qualification guide for medical purpose claims, accessories, software, Annex XVI products, and borderline routes to classification and conformity assessment.
EU MDR qualification workflow
A concrete EU MDR workflow for deciding whether a product is a medical device, accessory, Annex XVI product, IVD interface, medicinal-product interface, or non-MDR product before classification and conformity assessment.
EU MDR requirements checklist
Concrete EU MDR requirements for medical-device scope, classification, GSPR, conformity assessment, technical documentation, QMS, clinical evidence, UDI, EUDAMED, PMS, vigilance, and economic-operator records.
EU MDR Rule 11 software classification
Classify MDR medical device software under Rule 11 using intended purpose, diagnosis or therapy decision impact, physiological monitoring, conformity route, clinical evidence, and software-change records.
EU MDR significant changes FAQ: legacy-device transition and notified-body review
FAQ on MDR significant changes for legacy devices, including intended-purpose, design, software, material, sterilisation, clinical, QMS, notified-body, and evidence impacts.
EU MDR UDI and EUDAMED registration guide
EU MDR guide to Basic UDI-DI, UDI-DI, UDI carriers, EUDAMED actor and device registration, change impacts, and evidence governance.
EU MDR vigilance reporting workflow
Concrete EU MDR vigilance workflow for incident intake, serious incident assessment, FSCA and FSN handling, trend reporting, EUDAMED caveats, CAPA, PMS, clinical evaluation updates, and records.
How should Basic UDI-DI and UDI-DI be assigned under the EU MDR? | EU MDR FAQ
EU MDR FAQ explaining what Basic UDI-DI and UDI-DI identify, how they connect to UDI carriers, EUDAMED records, change triggers, and retained evidence.
MDR vs AI Act for medical-device software
Compare MDR software qualification, classification, clinical evidence, QMS, PMS, UDI, EUDAMED, and notified-body evidence boundaries against cautiously scoped AI Act overlap.
MDR vs GPSR: medical-device boundary checks
Compare MDR medical-device scope with general product-safety fallback questions for borderline, non-medical, and Annex XVI products.
MDR vs IVDR: medical devices and IVDs compared
Compare EU MDR and IVDR scope, classification, conformity routes, technical documentation, clinical or performance evidence, UDI, EUDAMED, PMS, and vigilance.
MDR vs Product Liability Directive evidence comparison
Compare EU MDR market-access evidence with Product Liability Directive exposure without treating compliance records as a liability outcome.
What should an EU MDR PMCF plan and report cover? | EU MDR FAQ
Under the EU MDR, PMCF is part of PMS and clinical evaluation. See what the plan, activities, report, updates, and retained evidence should cover.
What should manufacturers do when an EU MDR classification changes? | EU MDR FAQ
Concise EU MDR FAQ on classification changes, intended purpose, software, notified-body route impact, certificates, technical documentation, and retained evidence.
When can clinical equivalence be used under the EU MDR?
EU MDR FAQ on clinical equivalence, including technical, biological, and clinical characteristics, access to equivalent-device data, class III and implantable-device limits, clinical evaluation, PMCF, and retained evidence.
When do software or products make medical purpose claims under the EU MDR? | EU MDR FAQ
EU MDR FAQ on medical purpose claims, intended purpose evidence, software qualification, Annex XVI contrasts, and records to keep.
When is a PSUR required under the EU MDR and what should it contain? | EU MDR FAQ
EU MDR FAQ on PSUR scope, content, update cadence, PMS and PMCF links, notified-body handling, EUDAMED submission, and evidence to retain.
When is an accessory regulated under the EU MDR? | EU MDR FAQ
EU MDR FAQ on when an article is a medical device accessory, how intended purpose affects classification, and what evidence to keep.
When is software regulated as SaMD under the EU MDR? | EU MDR FAQ
Concise EU MDR FAQ on software qualification, intended medical purpose, Rule 11 classification, modules, clinical evidence, change assessment, UDI, and EUDAMED.
Which devices need an SSCP under the EU MDR and what should it include? | EU MDR FAQ
EU MDR FAQ on when an SSCP is required, who prepares, validates, uploads, and updates it, and what evidence should support the summary.
Which EUDAMED modules matter under the EU MDR? | EU MDR FAQ
EU MDR FAQ mapping EUDAMED modules to actor registration, UDI/device data, certificates, clinical investigations, vigilance/PMS, market surveillance, and practical records.